Stifel Nicolaus Sticks to Their Buy Rating for Evommune, Inc. (EVMN)
at www.tipranks.com (Mon, 6-Jul 1:55 AM)
EVMN’s EVO756 Misses Phase 2b Endpoint in Chronic Urticaria, but Development Continues for Atopic Dermatitis and Migraine
Market Chameleon (Mon, 29-Jun 9:00 AM)
